A new mechanistic insight into a known heart failure medicine in Pain therapy: Dobutamine (brand name: dobutrex, inotrex), used in the treatment of congestive heart failure and cardiogenic shock,  increases the expression of PD-L1, attenuates acute and chronic pain, and suppresses mechanical and thermal hypersensitivity and inhibits nociceptive neuron excitability, via up-regulation of its target gene, 18/September/2018, 6.24 am

Awakening the sleeping/cancer-protecting angels in mutant p53-expressing human tumors: Mibolerone (Trade name: Cheque drops and Matenon), an anabolic-androgenic steroid, increases the expression of tumor suppressors genes, such as HNF4α, CADM2, p53,  p53, TAp63, TAp73, INK4a/ARF, and others, induces regression of p53-mutated human tumors, via down-regulation of its target gene, 17/September/2018, 12.04 am
September 16, 2018
Consuming a Probiotic once a day may insulate your heart against cardiac dysfunction: Probiotic Lactobacillus Plantarum-based adjunct therapy for cardiac hypertrophy and fibrosis: Probiotic Lactobacillus Plantarum decreases Mir-29 expression, activates Wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1, and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function via upregulation of its target gene, 18/September/2018, 7.14 am
September 18, 2018
Show all

Introduction: What they say:

A recent study from Institute of Neurobiology, Institutes of Brain Science and State Key Laboratory of Medical Neurobiology, Collaborative Innovation Center for Brain Science, Fudan University, Shanghai, China; and Department of Neurobiology, Duke University Medical Center, Durham, North Carolina, US shows that “PD-L1 inhibits acute and chronic pain by suppressing nociceptive neuron activity via PD-1.” This study was published, in the 22 May 2017 issue of Nature Neuroscience (one of the best journals in Neurobiology, with an impact factor of 16.724+), by Prof Ji RR, Chen G and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: A new mechanistic insight into a known heart failure medicine in Pain therapy: Dobutamine (brand name: dobutrex, inotrex), used in the treatment of congestive heart failure and cardiogenic shock,  increases the expression of PD-L1, attenuates acute and chronic pain, and suppresses mechanical and thermal hypersensitivity and inhibits nociceptive neuron excitability, via up-regulation of its target gene


What is known?

It has recently been shown that blocking PD-1 with antibodies one could make tumors shrink. This work, relating to Cancer immunotherapy, has been chosen as Science’s breakthrough of the year. However, the work published recently, which is described below, may highlight the caveat in such an approach, as blocking PD-L1 may promote spontaneous pain and allodynia in cancer-bearing mice.

Prof. Ji has shown recently that: (1) Programmed cell death ligand-1 (PD-L1), produced by melanoma and normal neural tissues, inhibits acute and chronic pain; (2) injection of PD-L1 alleviates pain, and thereby functions as an analgesic agent; (3) Neutralization of PD-L1 or Block of PD1 promotes mechanical allodynia (hypersensitivity to pain); (4) PD1 null mice suffers from thermal and mechanical hypersensitivity; (5) PD-L1 promotes phosphorylation of SHP-1 and inhibits Sodium channels via PD-1 activation; and (6) PD-L1 inhibits nociceptive neuron excitability in dorsal root ganglion and thereby functions as a neuromodulator, suggesting that increasing the expression or the level of PD-L1/PD1 may alleviate pain and thermal and mechanical hypersensitivity.


From research findings to therapeutic opportunity:

Dobutamine has been used in the treatment of congestive heart failure and cardiogenic shock.  However, the mechanism of action remains largely unclear. The study presented here suggests, for the first time, that Dobutamine, by increasing the expression of their target genes, it may increase PD-L1 levels (figs. 1-2). Thereby, it may: (a) inhibit acute and chronic pain; (b) alleviate thermal and mechanical hypersensitivity; (c) activate signal transduction cascade downstream of the PD-1 receptor; (c) phosphorylate SHP-1; (d) inhibit sodium channels and nociceptive neuron excitability.

Figure 1.Mechanistic insights into how Dobutamine inhibits acute and chronic pain. Dobutamine enhances PD-L1 levels, suppresses thermal and mechanical hypersensitivity, phosphorylates SHP-1, inhibits activation of sodium channels, and alleviates nociceptive neuron excitability

Figure 2. Congestive heart failure (CHF) drug Dobutamine protects against pain through induction of PD-L1.

Thus, pharmacological formulations encompassing “Dobutamine or its analogs, either alone or in combination with other drugs,” may be used to attenuate short-term and long-term pain.


 

 

 

 

 

 

Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $500#

Undisclosed mechanistic information: How Dobutamine increases the expression of PD-L1 and attenuates pain.

# Research cooperation

For purchase details, you may reach us at admin@genomediscovery.org


References:

Citation: Boominathan, L., A new mechanistic insight into a known heart failure medicine in Pain therapy: Dobutamine (brand name: dobutrex, inotrex), used in the treatment of congestive heart failure and cardiogenic shock,  increases the expression of PD-L1, attenuates acute and chronic pain, and suppresses mechanical and thermal hypersensitivity and inhibits nociceptive neuron excitability, via up-regulation of its target gene, 18/September/2018, 6.24 am, Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or http://newbioideas.com

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.